Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 HALIX, AstraZeneca Ink Commercial COVID-19 Vax Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

HALIX, AstraZeneca Ink Commercial COVID-19 Vax Mfg. Pact

HALIX to provide large-scale GMP manufacture of AZD1222 at its cGMP facility in the Netherlands.

By: Contract Pharma

Contract Pharma Staff

HALIX B.V. signed an agreement with AstraZeneca for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine.

HALIX will provide commercial manufacturing of drug substance at its cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX has expanded with two additional viral vector production lines.

HALIX continues its key role as one of the original partners in the University of Oxford’s consortium for the manufacture of AZD1222. The vaccine was co-invented by the University of Oxford and its spin-out company Vaccitech.

Alex Huybens, Chief Operations Officer, said, “Building on the solid foundations made with the University of Oxford, it’s our pleasure to expand our manufacturing support of AZD1222 with AstraZeneca. Through the consortium, the partners are bringing their collective expertise and manufacturing capabilities to support vaccine production and combat this evolving crisis.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics